EZH2 and breast cancer: Whereas cohorts of virgin females bearing the wild-type or one conditional allele of Ezh2 developed measurable mammary tumours after an average onset of 67 and 61 days, respectively, Ezh2-deficient mice displayed a significant delay in tumour onset to an average of 145 days (Fig. 1b).